Edwards Lifesciences Corp (EW) concluded trading on Thursday at a closing price of $75.92, with 3.04 million shares of worth about $230.64 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -18.66% during that period and on December 26, 2024 the price saw a gain of about 0.72%. Currently the company’s common shares owned by public are about 589.80M shares, out of which, 579.56M shares are available for trading.
Stock saw a price change of 4.27% in past 5 days and over the past one month there was a price change of 6.52%. Year-to-date (YTD), EW shares are showing a performance of -0.43% which decreased to -0.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $58.93 but also hit the highest price of $96.12 during that period. The average intraday trading volume for Edwards Lifesciences Corp shares is 5.53 million. The stock is currently trading 3.76% above its 20-day simple moving average (SMA20), while that difference is up 7.89% for SMA50 and it goes to -2.72% lower than SMA200.
Edwards Lifesciences Corp (NYSE: EW) currently have 589.80M outstanding shares and institutions hold larger chunk of about 84.58% of that.
The stock has a current market capitalization of $44.78B and its 3Y-monthly beta is at 1.13. PE ratio of stock for trailing 12 months is 10.95, while it has posted earnings per share of $6.93 in the same period. Its PEG reads 1.56 and has Quick Ratio of 2.89 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EW, volatility over the week remained 2.03% while standing at 2.39% over the month.
Stock’s fiscal year EPS is expected to rise by 2.38% while it is estimated to decrease by -4.72% in next year. EPS is likely to shrink at an annualized rate of 7.00% for next 5-years, compared to annual growth of 15.35% made by the stock over the past 5-years.
Coverage by Morgan Stanley stated Edwards Lifesciences Corp (EW) stock as an Equal-weight in their note to investors on October 11, 2024, suggesting a price target of $70 for the stock. Stock get a Peer perform rating from Wolfe Research on July 29, 2024.
